Erlotinib: Efficacy in non-small cell lung cancer (2nd and subsequent lines of therapy)

• Autores: Juan Moll Sendra, Asunción Albert Marí, Enrique Soler Company
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 4, 2013, págs. 230-236
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: to assess the progression-free survival in non-small cell lung cancer in patients treated with erlotinib, with second or subsequent lines of therapy at a tertiary general hospital, and compare the subgroups analysis with previous studies.

    Method: an observational, retrospective study (48.5 months) in 21 patients.

    the main variable was the progression-free survival in months; second variables were overall survival, toxicity and disease control rate.

    Results: the median of progression-free survival was 2.7 months (1.77-3.64, CI 95%). the log-rank test showed greater progression-free survival if eGFr mutations existed (p = 0.006), non-smokers (p = 0.019) and females (p = 0.049).

    Conclusion: the results were consistent with most of previous studies conducted on other groups of patients